Sector
PharmaceuticalsOpen
₹979.4Prev. Close
₹965.5Turnover(Lac.)
₹447.37Day's High
₹999Day's Low
₹971.352 Week's High
₹1,58052 Week's Low
₹935.25Book Value
₹153.83Face Value
₹10Mkt Cap (₹ Cr.)
18,564.32P/E
85.63EPS
11.31Divi. Yield
0.2EBITDA margin slightly declined, down 80 basis points to 20.8% in Q2, reflecting some operational pressures.
The allotment of shares was finalised on July 8, and Emcure Pharma shares were scheduled to be listed on the BSE and NSE on July 10.
The IPO comprised a mix of fresh equity sale and an offer for sale (OFS).
The categories earmarked for NII and QIB investors received the most subscriptions, at 47.98 and 193.06 times, respectively.
The IPO is priced between Rs 960 and Rs 1008 a share, with buyers able to bid for 14 shares per lot.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 181.15 | 180.85 | 180.85 | 180.85 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,753.95 | 1,661.02 | 1,531.68 | 2,120.92 |
Net Worth | 1,935.1 | 1,841.87 | 1,712.53 | 2,301.77 |
Minority Interest |
No Record Found
No Record Found
No Record Found
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 6,658.25 | 5,985.81 | 5,855.39 | 6,056.42 | 5,048.55 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 6,658.25 | 5,985.81 | 5,855.39 | 6,056.42 | 5,048.55 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 56.99 | 45.91 | 63.47 | 35.39 | 82.31 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,614 | 122.93 | 3,87,276.66 | 1,181.05 | 0.84 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,568.7 | 71.3 | 1,47,802.29 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,461.75 | 25.37 | 1,18,061.19 | 1,438.15 | 0.89 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,059 | 56.75 | 1,03,513.97 | 485 | 0.92 | 2,330 | 222.38 |
Dr Reddys Laboratories Ltd DRREDDY | 1,140.1 | 18.33 | 95,026.5 | 849.4 | 0.7 | 4,997.8 | 322.46 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole Time Director
MUKUND KESHAO GURJAR
Whole Time Director
SUNIL RAJNIKANT MEHTA
Managing Director & CEO
SATISH RAMANLAL MEHTA
Chairman & Independent Directo
Berjis M Desai
Whole Time Director
NAMITA VIKAS THAPAR
Independent Director
P S Jayakumar
Independent Director
Vijay Gokhale
Independent Director
Vidya Rajiv Yeravdekar
Non Executive Director
Samonnoi Banerjee
Independent Director
Shailesh Ayyangar
Whole-time Director
SAMIT SATISH MEHTA
Company Sec. & Compli. Officer
CHETAN RAJENDRA SHARMA
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Emcure Pharmaceuticals Ltd
Summary
Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited, as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay. Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited, through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001.Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broadrange of pharmaceutical products across several major therapeutic areas. They are a research and development driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled to reach target markets across over 70 countries, with a strong presence in India, Europe and Canada. In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics. The Company has 13 manufacturing facilities across India. It keeps a strong track record in developing portfolios of differentiated products, including chiral molecules, complex APIs, biologics and novel drug delivery systems. It has a portfolio of 11 chiral molecules, of which 6 have been launched
Read More
The Emcure Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹980 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Emcure Pharmaceuticals Ltd is ₹18564.32 Cr. as of 06 Mar ‘25
The PE and PB ratios of Emcure Pharmaceuticals Ltd is 85.63 and 6.49 as of 06 Mar ‘25
The 52-week high/low is the highest and lowest price at which a Emcure Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Emcure Pharmaceuticals Ltd is ₹935.25 and ₹1580 as of 06 Mar ‘25
Emcure Pharmaceuticals Ltd's CAGR for 5 Years at N/I%, 3 Years at N/I%, 1 Year at -27.90%, 6 Month at -29.71%, 3 Month at -28.41% and 1 Month at -23.75%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.